Literature DB >> 7631218

Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin.

C Saadeh1, W Bridges, F Burwick.   

Abstract

Dermatomyositis is an uncommon idiopathic chronic inflammatory disorder. Oral corticosteroids are the treatment of choice. A few patients become resistant to steroids. We describe two patients who, after failure to respond to oral and high-dose intravenous corticosteroids, received a combination of oral cyclosporine and high-dose intravenous immune globulin, with apparent remission. The first patient was a 6-year-old girl with recurrent disease and vasculitis, despite prednisone therapy and normal muscle enzyme levels. The response was remarkable within 3 weeks of therapy. The second patient was a 30-year-old woman with progressive disease and secondary respiratory failure despite oral prednisone and methotrexate therapy. The response to treatment was optimal within 4 weeks. She received maintenance low-dose cyclosporine and a tapering dose of prednisone. The combination of high-dose immune globulin and cyclosporine can be useful and safe in the management of steroid-resistant dermatomyositis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631218     DOI: 10.1097/00007611-199508000-00018

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  6 in total

Review 1.  Intravenous immunoglobulin therapy in antiphospholipid syndrome.

Authors:  Emiliana Konova
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  Treatment of inflammatory myopathies.

Authors:  A C Cordeiro; D A Isenberg
Journal:  Postgrad Med J       Date:  2006-07       Impact factor: 2.401

Review 3.  Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.

Authors:  Theonymfi Doudouliaki; Charalampia Papadopoulou; Claire T Deakin
Journal:  Curr Rheumatol Rep       Date:  2021-03-08       Impact factor: 4.592

Review 4.  Juvenile dermatomyositis: recognition and treatment.

Authors:  Ann M Reed; Maricarmen Lopez
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 5.  Intravenous immunoglobulin therapy in rheumatic diseases.

Authors:  Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

6.  Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis.

Authors:  M G Danieli; G Malcangi; C Palmieri; F Logullo; A Salvi; M Piani; G Danieli
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.